Isolation and identification of specific bacteriophage against enteropathogenic Escherichia coli (EPEC) and in vitro and in vivo characterization of bacteriophage

Vahedi, Azadeh; Dallal, Mohammad Mehdi Soltan; Douraghi, Masoumeh; Nikkhahi, Farhad; Rajabi, Zahra; Yousefi, Maryam; Mousavi, Maryam

doi:10.1093/femsle/fny136

Cited by 44 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ciprofloxacin used as a positive control had a similar protective effect but it did not protect against weight loss. Similar results demonstrating the effectiveness of single doses of phage were obtained by Vahedi et al (2018), who controlled enteropathogenic E. coli in mice, and by Jun et al 2014, who successfully treated mice infected with Vibrio parahaemolyticus (marine bacterium causing infections associated with consumption of raw oysters). Jaiswal et al (2013) also showed that phages administered orally to rabbits by gastric tube 6 and 12 h post-infection controlled V. cholerae infections.…”

Section: Gastrointestinal Tract Infectionssupporting

confidence: 73%

Phage therapy efficacy: a review of the last 10 years of preclinical studies

Melo

Oliveira

Pires

et al. 2020

Critical Reviews in Microbiology

110

View full text Add to dashboard Cite

Due to the rise of multidrug-resistant infections in humans, phage therapy is gaining renewed attention in Western medicine. Despite the increasing number of publications focussed on the isolation, characterization and in vitro performance of different phages, there is still a lack of concise pre-clinical information to guide the application of phage therapy in clinical practice. Nevertheless, over the last decade, efforts have been made to conduct more detailed studies of the in vivo efficacy of phages. Here, we review the most relevant in vivo studies performed in the last decade covering phage efficacy in both preclinical and clinical trials. We compare different routes of administration, dosage effect and different animal models of distinct types of infections. Moreover, insights into case studies and results from clinical trials are presented. Challenges and limitations of phage use as evidenced by the current state of research are also discussed in order to improve both the trustworthiness and success of the implementation of phage therapy.

show abstract

Section: Gastrointestinal Tract Infectionssupporting

confidence: 73%

Phage therapy efficacy: a review of the last 10 years of preclinical studies

Melo

Oliveira

Pires

et al. 2020

Critical Reviews in Microbiology

110

View full text Add to dashboard Cite

show abstract

“…The results of Vahedi et al [119], though positive for phage therapy impact on the treated E. coli mouse gastrointestinal colonization, neither support nor refute compatibility of phage activity with presence of ciprofloxacin. The phage used was not named and treatment doses were delivered orally by gavage.…”

Section: Vahedi Et Al 2018 Escherichia Coli Ciprofloxacinmentioning

confidence: 89%

Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?

Abedon

2019

Antibiotics

101

View full text Add to dashboard Cite

Bacteria can evolve resistance to antibiotics. Even without changing genetically, bacteria also can display tolerance to antibiotic treatments. Many antibiotics are also broadly acting, as can result in excessive modifications of body microbiomes. Particularly for antibiotics of last resort or in treating extremely ill patients, antibiotics furthermore can display excessive toxicities. Antibiotics nevertheless remain the standard of care for bacterial infections, and rightly so given their long track records of both antibacterial efficacy and infrequency of severe side effects. Antibiotics do not successfully cure all treated bacterial infections, however, thereby providing a utility to alternative antibacterial approaches. One such approach is the use of bacteriophages, the viruses of bacteria. This nearly 100-year-old bactericidal, anti-infection technology can be effective against antibiotic-resistant or -tolerant bacteria, including bacterial biofilms and persister cells. Ideally phages could be used in combination with standard antibiotics while retaining their anti-bacterial pharmacodynamic activity, this despite antibiotics interfering with aspects of bacterial metabolism that are also required for full phage infection activity. Here I examine the literature of pre-clinical phage-antibiotic combination treatments, with emphasis on antibiotic-susceptible bacterial targets. I review evidence of antibiotic interference with phage infection activity along with its converse: phage antibacterial functioning despite antibiotic presence.

show abstract

“…mellonella that are infected with Burkholderia cepacia after treatment with bacteriophages [ 29 ], and other recent studies showed the therapeutic use of E . coli phages against mammalian models [ 30 ]. A simple animal model like wax worm can serve as a tool to determine the initial outcome of the phages in reducing bacterial infections.…”

Section: Resultsmentioning

confidence: 99%

Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131

et al. 2018

View full text Add to dashboard Cite

Phage therapy is the use of lytic bacteriophages to cure infections caused by bacteria. The aim of this study is to isolate and to characterize the bacteriophages against Escherichia coli isolated from clinical samples. For isolation of bacteriophages, water samples were collected from the Ganges River, and phage enrichment method was followed for phage isolation. Microbiological, genomic and lyophilization experiments were carried out to characterize the bacteriophage. Galleria mellonella was used to study the potential of phages against E. coli infection. Escherichia phage myPSH1131 belonging to Podoviridae family and found to have broad host range infectivity (n = 31) to infect Enterohemorrhagic E. coli (n = 9), Enteropathogenic E. coli (n = 6), Enterotoxigenic E. coli (n = 3), Enteroaggregative E. coli (n = 3), Uropathogenic E. coli (n = 9) and one unknown E. coli. The genome size is 76,163 base pairs (97 coding regions) and their genes show high similarity to SU10 phage. Lyophilization studies showed that the use of 1M sucrose, 2% gelatin and the combination of both 0.5M sucrose plus 1% gelatin could restore phage viability up to 20 months at 4°C. For in vivo studies, it was observed that a single phage dose can reduce the E. coli infection but to achieve 100% survival rate the infected larvae should be treated with three phage doses (20 μL, 103 PFU/mL) at 6 hours interval. The characterized Escherichia phage myPSH1131 was found to have broad host range activity against E. coli pathogens and in vivo studies showed that multiple doses are required for effective treatment.

show abstract

Isolation and identification of specific bacteriophage against enteropathogenic Escherichia coli (EPEC) and in vitro and in vivo characterization of bacteriophage

Cited by 44 publications

References 25 publications

Phage therapy efficacy: a review of the last 10 years of preclinical studies

Phage therapy efficacy: a review of the last 10 years of preclinical studies

Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?

Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131

Contact Info

Product

Resources

About